Cargando…

Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction

Current evidence regarding the effect of intravenous morphine administration on reperfusion injury and/or cardioprotection in patients with myocardial infarction is conflicting. The aim of this study was to evaluate the impact of morphine administration, on infarct size and reperfusion injury assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Eitel, Ingo, Wang, Juan, Stiermaier, Thomas, Fuernau, Georg, Feistritzer, Hans-Josef, Joost, Alexander, Jobs, Alexander, Meusel, Moritz, Blodau, Christian, Desch, Steffen, de Waha-Thiele, Suzanne, Langer, Harald, Thiele, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141264/
https://www.ncbi.nlm.nih.gov/pubmed/32182847
http://dx.doi.org/10.3390/jcm9030735
_version_ 1783519159377723392
author Eitel, Ingo
Wang, Juan
Stiermaier, Thomas
Fuernau, Georg
Feistritzer, Hans-Josef
Joost, Alexander
Jobs, Alexander
Meusel, Moritz
Blodau, Christian
Desch, Steffen
de Waha-Thiele, Suzanne
Langer, Harald
Thiele, Holger
author_facet Eitel, Ingo
Wang, Juan
Stiermaier, Thomas
Fuernau, Georg
Feistritzer, Hans-Josef
Joost, Alexander
Jobs, Alexander
Meusel, Moritz
Blodau, Christian
Desch, Steffen
de Waha-Thiele, Suzanne
Langer, Harald
Thiele, Holger
author_sort Eitel, Ingo
collection PubMed
description Current evidence regarding the effect of intravenous morphine administration on reperfusion injury and/or cardioprotection in patients with myocardial infarction is conflicting. The aim of this study was to evaluate the impact of morphine administration, on infarct size and reperfusion injury assessed by cardiac magnetic resonance imaging (CMR) in a large multicenter ST-elevation myocardial infarction (STEMI) population. In total, 734 STEMI patients reperfused by primary percutaneous coronary intervention <12 h after symptom onset underwent CMR imaging at eight centers for assessment of myocardial damage. Intravenous morphine administration was recorded in all patients. CMR was completed within one week after infarction using a standardized protocol. The clinical endpoint of the study was the occurrence of major adverse cardiac events (MACE) within 12 months after infarction. Intravenous morphine was administered in 61.8% (n = 454) of all patients. There were no differences in infarct size (17%LV, interquartile range [IQR] 8–25%LV versus 16%LV, IQR 8–26%LV, p = 0.67) and microvascular obstruction (p = 0.92) in patients with versus without morphine administration. In the subgroup of patients with early reperfusion within 120 min and reduced flow of the infarcted vessel (TIMI-flow ≤2 before PCI) morphine administration resulted in significantly smaller infarcts (12%LV, IQR 12–19 versus 19%LV, IQR 10–29, p = 0.035) and reduced microvascular obstruction (p = 0.003). Morphine administration had no effect on hard clinical endpoints (log-rank test p = 0.74) and was not an independent predictor of clinical outcome in Cox regression analysis. In our large multicenter CMR study, morphine administration did not have a negative effect on myocardial damage or clinical prognosis in acute reperfused STEMI. In patients, presenting early ( ≤120 min) morphine may have a cardioprotective effect as reflected by smaller infarcts; but this finding has to be assessed in further well-designed clinical studies
format Online
Article
Text
id pubmed-7141264
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71412642020-04-10 Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction Eitel, Ingo Wang, Juan Stiermaier, Thomas Fuernau, Georg Feistritzer, Hans-Josef Joost, Alexander Jobs, Alexander Meusel, Moritz Blodau, Christian Desch, Steffen de Waha-Thiele, Suzanne Langer, Harald Thiele, Holger J Clin Med Article Current evidence regarding the effect of intravenous morphine administration on reperfusion injury and/or cardioprotection in patients with myocardial infarction is conflicting. The aim of this study was to evaluate the impact of morphine administration, on infarct size and reperfusion injury assessed by cardiac magnetic resonance imaging (CMR) in a large multicenter ST-elevation myocardial infarction (STEMI) population. In total, 734 STEMI patients reperfused by primary percutaneous coronary intervention <12 h after symptom onset underwent CMR imaging at eight centers for assessment of myocardial damage. Intravenous morphine administration was recorded in all patients. CMR was completed within one week after infarction using a standardized protocol. The clinical endpoint of the study was the occurrence of major adverse cardiac events (MACE) within 12 months after infarction. Intravenous morphine was administered in 61.8% (n = 454) of all patients. There were no differences in infarct size (17%LV, interquartile range [IQR] 8–25%LV versus 16%LV, IQR 8–26%LV, p = 0.67) and microvascular obstruction (p = 0.92) in patients with versus without morphine administration. In the subgroup of patients with early reperfusion within 120 min and reduced flow of the infarcted vessel (TIMI-flow ≤2 before PCI) morphine administration resulted in significantly smaller infarcts (12%LV, IQR 12–19 versus 19%LV, IQR 10–29, p = 0.035) and reduced microvascular obstruction (p = 0.003). Morphine administration had no effect on hard clinical endpoints (log-rank test p = 0.74) and was not an independent predictor of clinical outcome in Cox regression analysis. In our large multicenter CMR study, morphine administration did not have a negative effect on myocardial damage or clinical prognosis in acute reperfused STEMI. In patients, presenting early ( ≤120 min) morphine may have a cardioprotective effect as reflected by smaller infarcts; but this finding has to be assessed in further well-designed clinical studies MDPI 2020-03-09 /pmc/articles/PMC7141264/ /pubmed/32182847 http://dx.doi.org/10.3390/jcm9030735 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Eitel, Ingo
Wang, Juan
Stiermaier, Thomas
Fuernau, Georg
Feistritzer, Hans-Josef
Joost, Alexander
Jobs, Alexander
Meusel, Moritz
Blodau, Christian
Desch, Steffen
de Waha-Thiele, Suzanne
Langer, Harald
Thiele, Holger
Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction
title Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction
title_full Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction
title_fullStr Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction
title_full_unstemmed Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction
title_short Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction
title_sort impact of morphine treatment on infarct size and reperfusion injury in acute reperfused st-elevation myocardial infarction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141264/
https://www.ncbi.nlm.nih.gov/pubmed/32182847
http://dx.doi.org/10.3390/jcm9030735
work_keys_str_mv AT eitelingo impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT wangjuan impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT stiermaierthomas impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT fuernaugeorg impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT feistritzerhansjosef impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT joostalexander impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT jobsalexander impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT meuselmoritz impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT blodauchristian impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT deschsteffen impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT dewahathielesuzanne impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT langerharald impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction
AT thieleholger impactofmorphinetreatmentoninfarctsizeandreperfusioninjuryinacutereperfusedstelevationmyocardialinfarction